TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06368414

Intervention type: DRUG
Group type: OTHER
Intervention: Asciminib
Description: that patients who lost MR3.0 after stopping TKIs, thus failed to maintain treatment-free remission can achieve second sustainable MR4.5 by sustainable MR4.5 for more than 3 years once regained and prolong MRFS by adding asciminib to TKIs. Patients will be restarted on TKIs when they fail sustaining MR3.0 after cessation because restarting TKIs when loss of MR3.0 is reasonable in this situation
Study: NCT04300504

Intervention type: OTHER
Intervention: observational study
Description: observational study

Intervention type: OTHER
Intervention: observational study
Description: observational study

Intervention type: OTHER
Intervention: observational study
Description: observational study

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT06457165

Intervention type: DEVICE
Intervention: Not Difficult Intubation
Description: Noted for each patient.

Intervention type: DEVICE
Intervention: Not Difficult Intubation
Description: Noted for each patient.
Study: NCT04867200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana(D006)
Description: NOAC(Factor Xa inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixiana(D006)
Description: NOAC(Factor Xa inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-344
Description: NOAC(Factor Xa inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-344
Description: NOAC(Factor Xa inhibitor)
Study: NCT05872256

Intervention type: DRUG
Group type: OTHER
Intervention: 0.045% Tazarotene/0.01% Halobetasol Lotion
Description: FDA approved drug for psoriasis treatment
Study: NCT04238611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: Lactate microneedle applied on the skin of participant

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood lactate measurement
Description: Serum lactate testing through conventional laboratory methods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise regimen
Description: Standardised aerobic exercise regimen
Study: NCT06095544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery for SPK recipients
Description: Pre-operative, perioperative and post-operative were consisted of evidenced-based systematic optimization approaches.
Study: NCT05552807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Administered intravenously
Study: NCT05400603

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
Description: The cell dose will be based on the subject's body weight. Subjects will receive a single infusion of third party, ex vivo expanded, frozen then thawed γδ T cell product at a dose of 3 x 106 cells/kg on Day 6 and then if they meet criteria for subsequent γδ T cell dose will receive a second dose of 3 x 106 cells/kg on Day 13. The dose will be escalated to 1 x 10\^7 and then 3 x 10\^7 cells/kg. In absence of any dose limiting toxicity, 3 x 10\^7 cells/kg will be accepted as the maximal dose.~Dinutuximab (17.5 mg/m2), temozolomide (100 mg/m2),irinotecan (50 mg/m2) and zoledronic acid (0.0125 mg/kg/dose) will be consistent across all dose levels.
Study: NCT06534047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway H4 deep Repetitive Transcranial Magnetic Stimulation (rTMS) coil
Description: An rTMS treatment course consisting of daily treatment, 5 days per week, for 3 weeks, followed by once weekly treatments for 3 weeks, for a total of 18 treatment sessions over 6 weeks.~Sixty trains of 30 pulses each (total 1,800 pulses) will be applied at 10 Hz, for 3 second trains, with a 15 second inter-train interval, for approximately 18 minutes of treatment time.~At each rTMS treatment session, prior to stimulation, participants will undergo a smoking craving provocation procedure where they will be asked to close their eyes and imagine one of their triggers for 30 seconds. Following this they will watch a presentation of smoking pictures for 2 minutes and 30 seconds. Thus, the entire craving provocation procedure will be 3 minutes prior to stimulation start.~Brief behavioural support will be available to the participant on a weekly basis by a trained research staff member.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement
Description: Each participant will receive individualized NRT treatment through the advice of their study physician for 6 weeks. The study physician, in discussion with the participant, will decide the type, dosage, and combination of NRT to provide to the participant.~NRT provided can include:~* Patch (7mg, 14mg, and 21mg)~* Gum (2mg)~* Lozenge (2mg)~* Inhaler (10mg; 4mg of nicotine delivered)
Study: NCT05552807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Administered intravenously
Study: NCT06495359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunization education program
Description: The content of the immunization education program for parents was created by researchers based on the literature. Expert opinions will be obtained from 7 people who are experts in the fields of child health and disease nursing and public health nursing for the training program. The training program consists of 30 minutes. The education program will be delivered to parents in the form of a 30-minute training session using the face-to-face education model. Interactive education methods that enable parents' participation will be used.
Study: NCT06499558

Intervention type: OTHER
Group type: OTHER
Intervention: Classical Training
Description: Students in the education group will practice family planning education skills in the professional skills laboratory.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Patient Interviews
Description: Students in the standardized patient education group will receive training involving a family planning counseling scenario with standardized patients.
Study: NCT05425862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pidnarulex
Description: Pidnarulex is a treatment that is designed to stop the action of a particular protein in the body called Polymerase I, that cancer cells rely on. Laboratory studies show that pidnarulex targets a process involving Polymerase I within cells, which can lead to a decrease in cancer growth. Pidnarulex has been shown to have some anticancer activity in ovarian cancer and haematological cancers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib belongs to a class of drugs called PARP inhibitors, which is currently being used to treat various types of cancer. Talazoparib blocks the function of PARP, a protein that is involved in repairing DNA in cells. By stopping damaged DNA in cells from being repaired, this will lead to accumulation of DNA damage in the cancer cell and ultimately cancer cell death. Talazoparib has established anticancer activity in breast, ovarian and prostate cancers with underlying DNA repair defects. This class of drug have also been used in combination with other treatments such as radiation or chemotherapy to further increase cell death within the cancer.
Study: NCT06015243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR1802 injection
Description: 150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous
Study: NCT05950230

Intervention type: DIAGNOSTIC_TEST
Intervention: Assess Periodontal Health Status
Description: For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assess Periodontal Health Status
Description: For all patients who are suitable for the study, the following clinical evaluation parameters will be recorded:~* Plaque index (PI)(Silness and Löe, 1964).~* Sulcus bleeding index(BOP)(Perez et al., 2008).~* Probing depth (PD) (Polson et al., 1980).~* Clinical attachment level (CAL) (Glavind and Löe, 1967).~* Standardized Periapical Radiograph.

Intervention type: OTHER
Intervention: Collecte GCF samples by paperstrip
Description: GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).

Intervention type: OTHER
Intervention: Collecte GCF samples by paperstrip
Description: GCF samples will be collected from all participating individuals to assess the levels of MMP-8 from the deepest periodontal pocket in the area. The sample areas will be insulated with cotton rolls, saliva contamination will be prevented, all supragingival plaque will be eliminated. The paper strips will placed into the periodontal pocket until resistance is felt and then permitted to remain for 30s(Offenbacher et al., 1984, Megson et al., 2010).
Study: NCT05415267

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: diphtheria and tetanus toxoids (adsorbed) vaccine
Description: The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: diphtheria and tetanus toxoids (adsorbed) vaccine
Description: The diphtheria/tetanus toxoids vaccine will be given to participants enrolled into Group 1 as a comparator vaccine to the mRNA COVID-19 booster vaccine with the aim of determining whether the results related to COVID-19 vaccine timing also apply to more traditional protein-based vaccines.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine
Description: All participants will receive a COVID-19 booster vaccination at either week 0 or week 24 depending on their randomised study arm
Study: NCT04976881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication Reconciliation (MedRec) Tool
Description: Patients will receive a print MedRec tool, generated via the EHR, which includes a list of medications prescribed according to the patient record. Patients are asked to review this list, to add/remove drugs to reflect actual use, to note how they are taking each medication, and to describe any concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider Alert and Decision Support
Description: During the clinic visit, an automated, EHR alert will notify the provider that the patient is a woman of reproductive age with T2DM and should receive counseling on the importance of glycemic control, the use of contraception until glycemic control is achieved, and the benefits of folic acid.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPSheet
Description: When patients leave an encounter, they will receive a patient-friendly educational material (a.k.a. the PREPSheet) that reviews potential risks of pregnancy in the context of T2DM and highlights the importance of: 1) achieving glycemic control through diabetes self-care, 2) using effective contraception until glycemic control is achieved and pregnancy is desired, 3) discussing medication use with a provider if planning or becoming pregnant, and 4) taking folic acid daily to reduce increased risk of neural tube defects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging
Description: Within \~5 days of their index clinic visit, intervention patients will begin to receive daily, unidirectional text messages to reinforce diabetes self-care behaviors.
Study: NCT06188598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Eating is restricted to an 8-hour window that is the same each day (e.g., 10am - 6pm)
Study: NCT05552807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT200
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered intravenously
Study: NCT06332612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Group B will receive Metformin 500 mg thrice daily. Group C will receive topical cream metformin thrice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone dipropionate
Description: Group 1will recieve topical cream betamethasone thrice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: Group 1 will receive Pentoxifylline tablet 400 mg twice daily
Study: NCT05135039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin 100mg/day/patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 100mg/day/patient
Study: NCT06307977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Couples Health Project
Description: A 3-session, couples motivational Interviewing drug use and HIV risk reduction intervention
Study: NCT05736185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP selection
Description: Electric impedance tomography-guided PEEP titration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP selection
Description: Electric impedance tomography-guided PEEP titration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEP selection
Description: Electric impedance tomography-guided PEEP titration
Study: NCT05957731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Both groups received routine physical therapy, which encompasses various components such as electrotherapy, strength training for both lower and upper limbs, gait training, and occupational therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antagonist contract relax
Description: antagonist contraction i used to improve spasticity and range of motion in stroke patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: agonist contract relax
Description: agonist contraction is used to improve spasticity and range of motion in stroke patients
Study: NCT06133855

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: The experimental group will be treated with an ASA magnetic field device (Automatic PMT Quattro Pro) at a frequency of 50 Hz in addition to the traditional physical therapy program. Each session will consist of 20 minutes of the patient lying prone and exposed to low-intensity 20-gauss PEMF.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program
Description: A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles.
Study: NCT05819242

Intervention type: DIAGNOSTIC_TEST
Intervention: Angulus
Description: Smartphone app

Intervention type: DIAGNOSTIC_TEST
Intervention: Angulus
Description: Smartphone app

Intervention type: DIAGNOSTIC_TEST
Intervention: Angulus
Description: Smartphone app
Study: NCT05395403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement device
Description: The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement device
Description: The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement device
Description: The use of three different devices: traditional office blood pressure measurement cuff (OBPM), automated office blood pressure measurement cuff (AOBPM), and home blood pressure measurement cuff (HBPM).
Study: NCT05297175

Intervention type: DEVICE
Group type: OTHER
Intervention: Trammpolin medial meniscus prosthesis
Description: Implantation of the Trammpolin medial meniscus prosthesis in patients with a severe medial meniscus damage
Study: NCT05176054

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health service program
Description: The program will be implemented into the experimental group, the program has been designed as a three-stage model including hospital management, transition care, and post-acute stage care.
Study: NCT06133855

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program
Description: A traditional physical therapy program will include~Infrared radiation for 20 minutes per session for 3 sessions per week for 4 weeks~Ultrasonic: 1 MHz; continuous mode of application: 1.5 w/cm2 for 5 minutes; 3 sessions per week for 4 weeks.~stretching exercises for the hamstring, calf muscles, and back muscles. 3 sessions per week for 4 weeks~Strengthening exercises for back and abdominal muscles.
Study: NCT04719481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium 80 MG
Description: daily oral administration of 80mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily oral administration
Study: NCT05087433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises
Description: The trainer performed the PRE exercise online with the nurses. The video recording of the progressive relaxation exercises was shared with the nurses participating in the study on WhatsApp groups. Nurses were asked to perform the PRE application in accordance with the commands in the video recordings. In addition, a guide in which the steps of applying progressive relaxation exercises for each muscle group were written was given to the nurses. It was stated that they should do the application regularly for 25-30 minutes in the morning every day at home for a month. The PRE application was reminded daily from the WhatsApp group for the nurses to apply regularly to the sessions and not to disrupt the sessions. Nurses shared the messages stating that they were doing the PRE application on a daily basis for four weeks on WhatsApp groups.
Study: NCT05842941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: DNL343 is administered orally once daily per day for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo is administered orally once daily per day for 24 weeks.
Study: NCT05224440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSMV Sponsorship Initiative
Description: Consistent with preventive, universal and public health approaches to suicide, the VA's TSMV Sponsorship Initiative establishes public-private partnerships with federal and community organizations to provide TSMVs with one-on-one, certified and volunteer sponsors in their post-military hometowns. Sponsors are assigned approximately six months prior to discharge and help TSMVs to accomplish reintegration tasks pre-and post-discharge. After certification, sponsors are assigned to and managed by a community integration coordinator (CIC), which is a local organization. CICs recruit sponsors, manage sponsors and match sponsors with TSMVs moving to the local region. After being matched with a TSMV, sponsors then integrate their skills during regular contact with matched TSMVs and monthly video or in-person sessions and help TSMVs identify SMART goals and develop reintegration action plans and ensure TSMVs attend VA healthcare appointments.
Study: NCT05107518

Intervention type: BEHAVIORAL
Intervention: Children Participation Assessment Scale
Description: Evaluation is carried out to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
Study: NCT04795492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: remote intervention
Description: Medication adherence and risk factor modification status were assessed, then individualized feedback, encouragement and recommendations were provided. Risk factor modification included lipid control, smoking and drinking cessation, BP monitoring, dietary change keeping a healthy weight and in our trial. There were also a lot of educational materials about coronary heart disease knowledge that were reviewed by cardiologists, and participants were free to provide them whenever and wherever they want.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine outpatient follow-up
Description: Participants in this group received standard outpatient cardiology follow-up with formal cardiac rehabilitation and secondary prevention.